BTG3 and myelodysplastic syndrome: Finally, we evaluated the possible involvement of specific biological pathways in the ANA ≥ 1:160 positive MDS patients (n = 19) comparing the obtained results with MDS patients with ANA negativity or ANA < 1:160 (n = 62).